Scarica l'app Stockscreener
903.99
0.11%
-1.04
Dopo l'orario di chiusura:
902.90
-1.09
-0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Lilly Eli Co Borsa (LLY) Ultime notizie
Fed. Circ. Says Judge Wrongly Axed Teva's $177M Eli Lilly Win - Law360
Lilly to work with Gov. Braun's administration to explore nuclear energy solutions - The Journal Gazette
FDA asks drug manufacturer for more safety data on Foundayo GLP-1 - USA Today
Novo Nordisk Brings in OpenAI as NVO Stock Sits Near 52-Week Lows Amid Generic Pressure, Eli Lilly Competition - foreignpolicyjournal.com
Eli Lilly's Oral Drug Clears CV Test, Hims Surges 14% - Gotrade
CrossBridge Bio: Up To $300 Million Acquisition By Eli Lilly To Advance Dual-Payload ADC Cancer Therapies - Pulse 2.0
Eli Lilly acquires Houston biotech startup for $300M - Houston Chronicle
Lilly Reports 57% Lower Death Risk in Foundayo Cardiovascular St - GuruFocus
Lilly’s Foundayo lowers heart attack, stroke risk in study - USA Today
Lilly Clears Cardiovascular Overhang on Foundayo - GuruFocus
Braun signs nuclear energy-related letter of intent with Eli Lilly and Company - Fox 59
ATUM Names Genentech and Eli Lilly Veteran Gavin Barnard as Chief Scientific Officer - citybiz
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - GlobeNewswire Inc.
Lilly eyes diabetes expansion for Foundayo after Phase III CV outcomes trial - FirstWord Pharma
US appeals court revives Teva lawsuit against Eli Lilly over migraine drug - Reuters
Braun administration, Eli Lilly to collaborate on nuclear power development - Indianapolis Business Journal
Leerink reiterates Eli Lilly stock rating on diabetes drug results - Investing.com
Lilly’s new obesity pill passes heart safety test in diabetes - BioPharma Dive
Is This $6.3 Billion Deal a Game Changer for Eli Lilly? - AOL.com
Eli Lilly (LLY) Stock Rises as Foundayo Obesity Pill Cuts Heart Death Risk by Over Half - CoinCentral
Gov. Mike Braun Signs Nuclear Energy Letter Of Intent With Eli Lilly And Company - InkFreeNews.com
Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request - Pharmaceutical Executive
Eli Lilly Expands TuneLab With Vasa AI Tie Up For Drug Discovery - simplywall.st
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson - Benzinga
Lilly confirms date and conference call for first-quarter 2026 financial results announcement - marketscreener.com
Eli Lilly schedules April 30 webcast for first-quarter 2026 results - Stock Titan
Govenor Mike Braun signs Nuclear Energy Letter of Intent with Eli Lilly and Company - WBIW
Lilly answers FDA's call for more Foundayo safety info, plotting diabetes filing in parallel - Fierce Pharma
Lilly says Foundayo pill lowers heart attack, stroke risk in study - Reuters
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Immunocore Holdings (IMCR) - The Globe and Mail
What Is Foundayo? Eli Lilly's New Diabetes Drug Is Drawing Fresh Retail Attention - Stocktwits
Governor Braun, Eli Lilly sign letter of intent to explore nuclear energy in Indiana - wevv.com
FDA asks Eli Lilly for more safety info on its new GLP-1 weight loss pill - The Independent
Lilly obesity pill shows no added heart risk in trial - MSN
Eli Lilly's New Oral Weight Loss Drug Clears Cardiovascular BarEli Lilly (NYSE:LLY) - Benzinga
Eli Lilly (LLY) Announces Positive Phase 3 Results for Foundayo in Type 2 Diabetes - GuruFocus
Migraine Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | Eli Lilly and Company, Axsome Therapeutics, AEON Biopharma, Charleston Laboratories, Amgen, Teva Pharma, Anne Lindblad - Barchart.com
Eli Lilly Reveals Results of Late-Stage Study for Type 2 Diabetes Treatment - WSJ
Lilly to seek FDA nod for obesity pill in diabetes after late-stage trial win - Seeking Alpha
Eli Lilly reports Foundayo met primary objective in Phase 3 ACHIEVE-4 study - TipRanks
Lobbying Update: $120,000 of ELI LILLY AND COMPANY lobbying was just disclosed - Quiver Quantitative
Lilly’s Foundayo meets cardiovascular safety goal in diabetes trial By Investing.com - Investing.com Canada
Lilly’s Foundayo Obesity Pill Matches Insulin in Heart Study - Bloomberg.com
Daily diabetes pill beats insulin on weight, A1C and heart safety - Stock Titan
Hedeker Wealth LLC Has $9.73 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Hardman Johnston Global Advisors LLC Acquires 20,752 Shares of Eli Lilly and Company $LLY - MarketBeat
Market Street Wealth Management Advisors LLC Has $18.14 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Sumitomo Mitsui Trust Group Inc. Sells 102,900 Shares of Eli Lilly and Company $LLY - MarketBeat
Prediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug Market - The Motley Fool
Greenup Street Wealth Management LLC Takes Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Sold by Altfest L J & Co. Inc. - MarketBeat
Gov. Mike Braun signs nuclear energy letter with Eli Lilly - nwitimes.com
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
FDA asks drugmaker Eli Lilly for more safety information on its new GLP-1 weight loss pill - AOL.com
The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust - The Motley Fool
Eli Lilly Navigates Regulatory and Pipeline Milestones Ahead of Earnings - AD HOC NEWS
Selling pressure pushes Eli Lilly stock lower in today's trading - Traders Union
Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors - MedCity News
BMO reiterates Eli Lilly stock Outperform on manageable post-marketing requirements - Investing.com Australia
Lilly to acquire CrossBridge Bio for up to $300m - Pharmaceutical Technology
AI Models Split on Eli Lilly (LLY) as Valuation and Technicals Diverge from Fundamentals - TipRanks
Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data - BioSpace
Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million - AIM Media House
Eli Lilly bets $300m on CrossBridge Bio's dual-payload ADC platform - BioXconomy
Eli Lilly Adds CrossBridge ADCs To Broaden Oncology Growth Story - simplywall.st
1.73%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):